A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

In brief

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Key facts

Study ID: NCT04830137
Run by: Nurix Therapeutics, Inc.
People needed: 248
Starts: 2021-05-05
Expected to finish: 2027-05-01
Last updated by the study team: 2026-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must be ≥ 18 years of age
Patients must have measurable disease per disease-specific response criteria
Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)
Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)
Adequate organ and bone marrow function
Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol
Inclusion Criteria for Patients in Phase 1a:
Have histologically confirmed R/R CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL
Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit
Must require systemic therapy
Inclusion Criteria for Patients in Phase 1b:
Must have one of the following histologically documented R/R B-cell malignancies:
CLL/SLL whose disease has failed treatment with a BTKi;
MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen
FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi
PCNSL whose disease failed at least 1 prior line of treatment
DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another/ palliative regimen (either progressed post stem cell transplant or transplant-ineligible)

You may not qualify if…

Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
History of known/suspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)
Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug
Bleeding diathesis, or other known risk for acute blood loss
Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug
Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)
Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).
Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible
Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug
Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 > 350/mm3 and undetectable viral load) are eligible.
Current active liver disease from any cause
Active viral reactivation (e.g., CMV or EBV)
Use of systemic corticosteroids exceeding 20 mg/day prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg/day prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.
Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study
Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug
Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days

Where it is running

The University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
National Institutes of Health Clinical Center — Bethesda, Maryland, United States (enrolling)
Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
Sarah Cannon Research Institute at Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah, United States (enrolling)
City of Hope — Duarte, California, United States (enrolling)
OSU Wexner Medical Center — Columbus, Ohio, United States
Baylor University Medical Center — Dallas, Texas, United States
Swedish Cancer Institute — Seattle, Washington, United States
University of California Irvine — Orange, California, United States
University of California San Francisco Medical Center — San Francisco, California, United States
Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
Sarah Cannon Research Institute at Florida Cancer Specialists — Sarasota, Florida, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
University of Cincinnati Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.